Skip to main content
AGIO logo

AGIO · Agios Pharmaceuticals, Inc.

Track AGIO — free
$29.33 -0.36 (-1.20%)
Market Cap
$1.78B
Shares
59.81M
Volume · Nov 19 147.79K Avg daily vol (3M) 1.07M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$29.68 Open$29.57 Day$29.22–30.48 52W close$22.34–45.49 Avg vol 30d1.2M Short int6.5M · 10.9% of shares · 5.2d Short vol55% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 11, 2027 Est · unconfirmed · in 12 wks

Latest documents

2026
Nov 5
Earnings call
Record revenue; sickle cell review extended to February 1st, 2027

Agios reported record third-quarter revenue of $55.4 million, more than four times last year's third quarter. The FDA extended the sickle cell review to February 1st, 2027, while the company held $907 million in cash, cash equivalents and marketable securities.

3 source passages
The third quarter delivered record product revenue for Agios and is a clear demonstration of our commercial execution. We delivered $55.4 million in total net revenue, more than four times the third quarter of last year. The FDA classified our response as a major amendment, which procedurally extends the review timeline by three months to February 1st, 2027. We ended the quarter with $907 million in cash, cash equivalents, and marketable securities, and are well-capitalized to support commercial launches and development of our focused pipeline. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue surges with AQVESME launch; sickle-cell review delayed

Agios reported nine-month revenue growth of $86.8 million, driven by AQVESME and PYRUKYND. The FDA’s mitapivat sickle-cell goal date was extended to February 1, 2027, while nine-month net loss was $264.9 million.

Revenue $55.39M ▲ 330.0% Net loss $65.05M Diluted EPS -$1.09
Read from the MD&A section
4 source passages
Agios accounted for the agreement as an asset acquisition. The increase in total revenue of $86.8 million for the nine months ended September 30, 2026 compared to the nine months ended September 30, 2025 was due to an increase of $75.3 million in United States product revenue and an increase of $11.5 million in rest of world product revenue. The increase in United States product revenue was primarily due to AQVESME® sales, for which we began recognizing product revenue in the first quarter of 2026, and increased volume associated with PYRUKYND®. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD. Our net loss for the nine months ended September 30, 2026 was $264.9 million and for the nine months ended September 30, 2025 was $304.7 million. Open the document at this passage
Nov 5
Current report 8-K
Mitapivat posts $55.4 million revenue; FDA review extended

Agios Pharmaceuticals reported third-quarter 2026 mitapivat net revenue of $55.4 million, more than four times $12.9 million. FDA extended the sickle cell disease sNDA goal date to February 1, 2027; cash was $907.0 million at September 30, 2026.

Financial results
4 source passages
Agios Pharmaceuticals, Inc. today announced financial results and updates for the third quarter ended September 30, 2026. Mitapivat (PYRUKYND® and AQVESME®) delivered worldwide net revenues of $55.4 million in third quarter of 2026, more than four times the $12.9 million reported in third quarter of 2025 Agios announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its mitapivat sickle cell disease supplemental New Drug Application (sNDA) by three months, from November 1, 2026, to February 1, 2027. $907.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026, fully funding commercial launches and pipeline programs; company is targeting non-GAAP profitability in 2028 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$140.84M
Trailing 12 months
Net income (TTM)
−$372.90M
Trailing 12 months
Revenue growth YoY
+330.0%
Year over year
Operating margin
-297.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-18.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$128.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.7%
Year over year · more shares
Price change (1Y)
-34.8%
Trailing year
Short interest
10.9%
Latest settlement · 5.2 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Mitapivat revenue grew more than fourfold, AQVESME demand broadened, and new mitapivat and AG-236 data advanced the pipeline; the company held $907.0 million and targets non-GAAP profitability in 2028. Key negatives were the sickle-cell PDUFA delay and REMS information request, along with continuing net loss, higher SG&A, lower cash, and rising cost of sales.

Bullish
  • + Mitapivat net revenue grew to $55.4 million, more than fourfold year over year.
  • + AQVESME demand broadened across patient segments, with 619 cumulative completed start forms.
  • + The company held $907.0 million in liquidity and targets non-GAAP profitability in 2028.
  • + R&D headcount will fall by more than 35%, with associated savings expected in 2027.
  • + Mitapivat showed durable hemoglobin improvement and potential kidney and cardiac benefits in sickle cell disease.
  • + AG-236 Phase 1 data supported potential every-six-month dosing in polycythemia vera.
Bearish
  • − The FDA extended the mitapivat sickle cell PDUFA goal date by three months to February 1, 2027.
  • − The FDA requested additional information to assess whether a REMS is required for sickle cell disease.
  • − Net loss remained $65.0 million in the third quarter.
  • − SG&A expense increased to $56.5 million from $41.3 million, reflecting launch investment.
  • − Cash, cash equivalents, and marketable securities declined to $907.0 million from $1.2 billion.
  • − Cost of sales increased to $2.5 million from $1.7 million in the prior-year quarter.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −7%
below
Price vs 50-day avg −10%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 32%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −20%
trailing
6-month return +1%
trailing
YTD return +9%
this year
Relative strength +4%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $33 › 200d $32 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.91% of shares out · ▼ -5.4% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
244 holders — near 3-yr high, broad support
Squeeze score 56
elevated · 0–100
Fundamentals
Weak
Revenue growth −38%
Y/Y
EPS growth −161%
Y/Y
Free cash flow $-377.3M
Buyback $415.5M
remaining
Balance sheet $89.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 80%
annualized · 1-yr
Max drawdown −51%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 5, 2026
One-time expense associated with the headcount reduction · fourth quarter of 2026 $11M
Previous outlook earlier release · from the Earnings Call filed Jul 30, 2026

Still-open targets the latest release did not restate under the same label.

Gross to net · 2026 10% – 20%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−7% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
32% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $33 › 200d $32 — 50d above 200d
Institutional flow Accumulating
+2% holders QoQ · +35 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.91% of shares out · ▼ -5.4% MoM · 5.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
244 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $22 Now $30 · 32% Range high $45
vs 200-day avg -7% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Additional cumulative prescriptions with ASFs in process 48 as of September 30, 2026 —
AQVESME patients remaining on therapy after six months 75% after six months of treatment —
Cumulative AQVESME prescriptions with completed start forms from REMS-certified physicians 619 as of September 30, 2026 —
cumulative AQVESME prescriptions for thalassemia written by REMS-certified U.S. physicians 442 as of June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AGIO
Agios Pharmaceuticals, Inc.
this stock
$1.78B +9.0% -38.5% — 10.9%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
244
% held
112.5%
Net QoQ
+1.3M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
245
View
Short & Settlement
Short Interest Falling
Shares short
6.5M
Days to cover
5.2d
Change
-370.7K sh
View
Short Volume
Short vol %
55%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
94
Value
$3.2K
As of
Aug 17, 2026
View
Off-Exchange
Off-exchange %
50.3%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Aug 20, 2026
View
Financials
Financials
Revenue (FY)
$54.0M
Net income (FY)
$-412.8M
EPS diluted
$-7.12
View
Buybacks
Authorized · 2 programs
$1.8B
Remaining
$415.5M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
21

Agios reported nine-month revenue growth of $86.8 million, driven by AQVESME and PYRUKYND. The FDA’s mitapivat sickle-cell goal date was extended to February 1, 2027, while nine-month net loss was $264.9 million.

View
Proposed Sales
Value
$296.5K
Shares
7.9K
Filed
Oct 26, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 14, 2026
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Agios Reports Third Quarter 2026…
Published
Nov 5, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
AGIO -9.6% -20.2% +1.0% -2.9% +9.0%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -5.7% -14.6% +4.4% +0.5% +2.0%

Capital returns

Buyback programs · 2 active · as of Jun 30, 2021
Authorized (total)
$1.80B
Spent (derived)
$1.38B
Remaining
$415.50M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1439222 CUSIP 00847X104 13F (30d) 248 filings 229 filers Visit website Investor relations